Plain-English translation of NCT07254806 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 3 โ Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new treatment called IDCT (Intradiscal Cell Therapy) that involves injecting specialized cells directly into a damaged spinal disc in your lower back. Researchers want to see if this treatment can safely reduce pain and improve function in people with mild to moderate disc degeneration who haven't been helped by standard care like physical therapy, pain medications, or injections. Half of participants will receive the actual cell injection, while the other half will receive a needle insertion without cells (a sham procedure) so researchers can fairly compare the results.
Degenerative disc disease โ the breakdown of cushioning discs in the spine โ is a common cause of chronic lower back pain that doesn't always respond well to physical therapy, medication, or other traditional treatments. This trial exists to see whether this new treatment can offer relief to people stuck with long-term pain despite trying standard approaches.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you qualify, you'll be randomly assigned to receive either the cell injection or a sham procedure (needle insertion without cells). The actual injection involves a single 1 mL dose containing 9 million cells delivered directly into your target disc. You'll have study visits to monitor your pain levels, function, and any side effects over the course of the trial. The study involves 162 participants total across multiple medical centers, so you'll be part of a rigorous comparison that helps researchers determine if this new treatment truly works.
AI-generated summary from trial data ยท Oct 2, 2026 ยท Not medical advice
United States